Vertex Pharmaceuticals Inc (VRTX) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Industry, else..
 
Vertex Pharmaceuticals Inc  (NASDAQ: VRTX)
 

Vertex Pharmaceuticals Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VRTX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) 12.45 % 12.22 % 8.91 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) 11.62 % -2.93 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 10.23 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 3.02 % 2.69 % 2.03 % 2.61 %
Revenue 5 Year Average Growth 14.1 % 7.41 % 8.65 % 10.59 %


VRTX's Growth Comparisons in II. Quarter 2026




Vertex Pharmaceuticals Inc improved it's Revenue by 12.45% year on year in the second quarter 2026, and outpaced the 12.22% rise in the Major Pharmaceutical Preparations industry, and 8.91% growth in the Healthcare sector. Comparing the second quarter sales growth, both Major Pharmaceutical Preparations industry and Vertex Pharmaceuticals Inc outperformed 10.9% overall market increase.

Top-line improved by 11.62% from the first quarter. Looking into annual sales rise of 14.1%, and S & P 500's average yearly sales growth is 10.59% over the five years, including only Businesses with the second quarter 2026 Results. Vertex Pharmaceuticals Inc grew faster than the market.

VRTX Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Product
-
-
ALYFTREK
536.48 %
135.16 %
TRIKAFTA/KAFTRIO
-
-
Manufactured Product, Other
-
-
Cystic Fibrosis Products
-
-
CASGEVY
292.43 %
178.09 %
JOURNAVX
555 %
171.03 %
United States
-
115.79 %
Europe
-
102.92 %
Other Countries Outside of the United States and Europe
-
-
Non-US
-
-
Pharmaceuticals
113.2 %
111.62 %
Total
12.45 %
11.62 %


Growth Rates of VRTX's Income in the second quarter 2026


VRTX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) 8.32 % -8.88 % 4.62 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) 9.56 % -4.52 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) 21.76 % 30.63 % 30.73 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) 2.05 % -2.27 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change 7.88 % 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) 6.48 % -34.9 % -25.98 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) 6.63 % -2.61 % -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) 21.1 % 6.3 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) 1.54 % -10.02 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change 7.83 % -0.55 % 0.17 % -28.52 %

VRTX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) 6.48 % -35.09 % -26.26 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) 6.63 % 2.87 % -0.77 % 27.07 %
Y / Y Net Income Change (Q2 TTM) 21.1 % 5.21 % 15.51 % 57.33 %
Sequential Net Income Change (Q2 TTM) 1.54 % -10.17 % -6.72 % 18.65 %
Net Income 5 Year Avg. Growth 7.83 % 14.55 % 9.21 % 22.96 %

VRTX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) 7.96 % -40.27 % -25.98 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) 6.9 % -7.72 % -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) 22.43 % - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) 1.88 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth 8.17 % -10.78 % 0.17 % -28.52 %



VRTX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) 8.02 % -40.45 % -26.26 % -28.52 %
Q / Q EPS Net Growth (Q2 MRQ) 7.21 % -2.53 % -0.77 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) 1.9 % - - 4.93 %
EPS Net 5 Year Avg. Change 8.29 % 14.55 % 9.21 % 22.96 %



Vertex Pharmaceuticals Inc bucks the industry trend and shows 8.02% year on year EPS increase in the second quarter to $4.31, while Major Pharmaceutical Preparations industry declined by -40.45%, Healthcare sector dropped -26.26%. Slow second quarter 2026 income per share, in Major Pharmaceutical Preparations industry and Healthcare sector, were portrayed in the Vertex Pharmaceuticals Inc results which underperformed overall market.

Comparing company's EPS to the first quarter results, income per share were higher by 7.21% . On the yearly basis, average annual income per share growth for Vertex Pharmaceuticals Inc is 8.29%, while S & P 500's including only the businesses with the second quarter 2026 Results, average annual income per share growth is 22.96% over the past five years.

VRTX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) 9.25 % 25.53 % 48.49 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) -21.74 % -42.37 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) 8.47 % 11.91 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) 2.31 % 3.24 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change 1.3 % 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) 33.73 % - - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change -29.05 % 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) -22.99 % 11.25 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) -15.89 % -25.6 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) 43.29 % 16.65 % 7.87 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) -6.32 % 2.92 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change 10.99 % 8.82 % 9.12 % 14.73 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.